9 Things Perimenopausal Women With Hemochromatosis Need to Know When Periods Stop
This one keeps me up at night a little, honestly. So many women with hemochromatosis are told they are 'protected' by their periods, and they are — until suddenly they aren't. The transition out of regular menstruation is not a gradual handover of that protection; it can be an abrupt removal of it, and that deserves a lot more attention than it typically gets.
Learn more about Rose →Menstrual blood loss has been your primary iron regulator — and perimenopause starts dismantling it unpredictably
In hereditary hemochromatosis (HH), the gut absorbs significantly more dietary iron than the body needs because the hepcidin signalling system is impaired, leaving menstrual blood loss as the most reliable compensatory mechanism. During perimenopause, cycles become irregular and flow patterns erratic — some months heavier, some months absent — meaning iron offloading becomes inconsistent years before the final period. Women with HH cannot assume that an ongoing but irregular cycle is still providing adequate protection, because the cumulative monthly loss may be dramatically reduced even before periods formally stop.
Serum ferritin can rise sharply in the years around the final period, not just after it
Research in women with HH consistently shows that ferritin levels begin climbing during the perimenopausal transition, not only in postmenopause, as the regularity and volume of periods decline. A woman who has maintained stable ferritin in her 30s through natural monthly blood loss may see values increase noticeably in her mid-to-late 40s even while she still has occasional periods. This means annual ferritin monitoring is not sufficient during perimenopause — more frequent checks, ideally every three to six months, are warranted in discussion with a haematologist or GP familiar with iron overload.
The symptoms of iron overload and perimenopause overlap significantly, which delays diagnosis of both
Fatigue, joint pain, brain fog, low mood, poor sleep, and reduced libido are documented symptoms of both iron overload and perimenopause — a convergence that creates real diagnostic confusion for women and clinicians alike. A woman attributing relentless exhaustion and aching joints entirely to 'the menopause' may be missing a concurrent rise in iron deposition that is independently damaging tissue. Blood tests for ferritin, transferrin saturation, and hormones like FSH and oestradiol should be interpreted together rather than in isolation when a woman with HH enters this life stage.
Therapeutic phlebotomy schedules established in premenopause may need urgent revision
Many women with HH who were managed conservatively during their reproductive years — perhaps with infrequent venesection because menstruation was doing enough of the work — will find their existing treatment plan is no longer adequate once periods become irregular or cease. A phlebotomy frequency that kept ferritin in the target range at age 42 may be wholly insufficient at age 48 with erratic cycles. Any woman with HH entering perimenopause should proactively revisit her iron management plan with her specialist, rather than waiting for elevated ferritin results to prompt a conversation.
Oestrogen has a modest iron-regulatory effect of its own, and its decline adds another layer of risk
Oestrogen influences hepcidin expression and has been shown to play a role in modulating iron absorption and recycling at a cellular level, meaning the hormonal shift of perimenopause compounds the loss of menstrual iron excretion with a reduction in oestrogen's own iron-dampening effect. This dual mechanism — less blood loss and less oestrogen — creates a compounding pressure on iron levels that is greater than either factor alone. The physiology here is still being characterised, but the direction of effect is consistent across available studies: menopause accelerates iron accumulation in women with HH through more than one pathway.
Liver and joint damage from iron accumulation can progress silently during this window
Iron deposits in the liver, joints, pancreas, and heart do not cause pain or obvious symptoms until damage is well established, which means organ injury can accrue during the perimenopausal years without any clear warning signal. The joints most commonly affected in HH — the second and third metacarpophalangeal joints of the hand — may begin to ache in ways that are easily attributed to 'getting older' or to the joint changes that perimenopause itself can bring. A baseline liver ultrasound and liver function panel are reasonable to have during the early perimenopausal years so that any progression during the transition can be detected and compared against a known starting point.
Hormone replacement therapy does not meaningfully worsen iron overload, but the conversation with your specialist still matters
A common concern among women with HH considering HRT is whether oestrogen supplementation might increase gut iron absorption and worsen overload — but current evidence does not support this as a clinically significant risk when iron levels are adequately managed. Some research even suggests that oestrogen may have a mildly protective effect on iron metabolism, which is consistent with observations that HRT users tend to have modestly lower ferritin than non-users in postmenopause. What matters most is that the decision to use HRT is made in the context of a current, accurate picture of iron status, and that ferritin monitoring continues at appropriate intervals after starting.
Dietary iron intake guidance does not change dramatically at menopause, but awareness of absorption enhancers becomes more important
Women with HH are generally advised to avoid iron supplements, limit alcohol (which increases iron absorption and adds direct liver risk), and be cautious with very high-dose vitamin C taken alongside iron-containing meals, since ascorbic acid significantly enhances non-haem iron absorption. These principles remain consistent at menopause, but the margin for error narrows once the menstrual safety valve is removed. Reviewing dietary habits with a dietitian experienced in iron disorders during the perimenopausal transition is a practical step that is often overlooked in favour of purely pharmaceutical management.
Women with HH who were never symptomatic before menopause are not guaranteed to remain so afterward
A significant number of women with confirmed HH genotypes — particularly HFE C282Y homozygotes — remain relatively asymptomatic through their reproductive years precisely because menstruation provides sufficient iron clearance, creating a false sense of security that the condition is mild or non-progressive. The postmenopausal data tell a different story: rates of elevated ferritin, liver fibrosis, and symptomatic iron overload increase substantially in women with HH after the final period compared to premenopausal peers with the same genotype. Being 'fine until now' is not a reliable predictor of how iron will behave once the body's natural excretion mechanism disappears.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.